Swedish Orphan Biovitrum EBITDA Margin 2019-2025 | BIOVF

Swedish Orphan Biovitrum ebitda margin for the quarter ending June 30, 2025 was 36.45%.

  • Swedish Orphan Biovitrum average ebitda margin for 2024 was 34.26%, a 1.18% increase from 2023.
  • Swedish Orphan Biovitrum average ebitda margin for 2023 was 34.67%, a 4.68% decline from 2022.
  • Swedish Orphan Biovitrum average ebitda margin for 2022 was 33.12%, a 18.4% increase from 2021.

Ebitda margin can be defined as earnings before interest, taxes, depreciation and amortization as a portion of total revenue.

Swedish Orphan Biovitrum EBITDA Margin 2019-2025 | BIOVF

  • Swedish Orphan Biovitrum average ebitda margin for 2024 was 34.26%, a 1.18% increase from 2023.
  • Swedish Orphan Biovitrum average ebitda margin for 2023 was 34.67%, a 4.68% decline from 2022.
  • Swedish Orphan Biovitrum average ebitda margin for 2022 was 33.12%, a 18.4% increase from 2021.

Ebitda margin can be defined as earnings before interest, taxes, depreciation and amortization as a portion of total revenue.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$246.7B
Amgen (AMGN)$159.1B
Gilead Sciences (GILD)$146.4B
Vertex Pharmaceuticals (VRTX)$100.2B
Bristol Myers Squibb (BMY)$98.4B
GSK (GSK)$80.7B
CSL (CSLLY)$70.8B
Regeneron Pharmaceuticals (REGN)$60.6B
Alnylam Pharmaceuticals (ALNY)$60.1B
Argenex SE (ARGX)$40.2B
Insmed (INSM)$26.9B
BioNTech SE (BNTX)$26.8B
Royalty Pharma (RPRX)$21B
Biogen (BIIB)$20.4B
Incyte (INCY)$16.7B
Illumina (ILMN)$15.6B
Genmab (GNMSF)$15.3B
Genmab (GMAB)$15.3B
Ascendis Pharma (ASND)$11.9B
BioMarin Pharmaceutical (BMRN)$11B
QIAGEN (QGEN)$10.9B
Moderna (MRNA)$10.9B
Exelixis (EXEL)$10.1B
Verona Pharma American Depositary Share (VRNA)$9B
Exact Sciences (EXAS)$8.6B
Bio-Techne Corp (TECH)$8.6B
Blueprint Medicines (BPMC)$8.3B
Halozyme Therapeutics (HALO)$8.2B
Roivant Sciences (ROIV)$8B
Anbio Biotechnology (NNNN)$7.5B